Cost-Savings In Effective Clinical Reminders For HIV Testing

Published May 29, 2014
Boston, MA, USA - About 1.1 million individuals are living with HIV in the United States and it is estimated that approximately 15-20% are currently unaware of their status. To increase HIV testing rate, the Veterans Health Administration (VHA), the single largest health care system in the United States, has removed the requirement for formal pretest and posttest counseling and has substituted verbal consent for written informed consent prior to HIV testing.  In addition, many sites have installed clinical reminders to promote routine-based testing. Dr. Kee Chan, PhD, Assistant Professor of Health Science at Boston University and investigator at the Center for Healthcare Organization and Implementation Research at the Veterans Affairs Medical Centers in Boston and Bedford, led a group of researchers to conduct a comparative cost analysis for three alternative strategies for HIV testing:  1) physician-based traditional HIV testing and counseling in the absence of clinical reminders; 2) clinical reminders and nurse-based stream-lined counseling with telephone notifications for negative results; and 3) clinical reminders without pre-test counseling and with telephone notifications for negative results Dr. Chan highlights, "My Boston research group collaborated with VA Greater Los Angeles to evaluate the annual total costs and costs per new case. The cost of a clinical reminder system with pre-test counseling was $81,726 compared to $109,208 for traditional HIV testing in one year.  A clinical reminder system without counseling had the most cost-savings per case identified of $57.69, compared to traditional testing at $120.93. The findings support the current implementation of the clinical reminder system to promote HIV testing in the VA." This study, "Comparative Cost Analysis of Clinical Reminder for HIV Testing at the Veterans Affairs Healthcare System," is published inValue in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now